• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.70 EUR+2.05 %21.8, 17.29
5,676 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
+2.05 %
0.00 %
+13.83 %
-39.21 %
-55.01 %
-54.41 %
-46.41 %
-87.15 %
-62.97 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
36.46M EUR
Turnover
48.21K EUR
P/E (adj.) (26e)
-13.4
EV/EBIT (adj.) (26e)
-9.68
P/B (26e)
1.71
EV/S (26e)
1.79
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
17.08.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
So the missing piece with Big Pharma has been handled. Great.
yesterday
15
The Optomed USA website features a compilation of customer comments on using the Aurora camera in actual patient care. These are worth reading as they are based on real-world experience. Mentions of high image quality and ease of use, among other things, recur in these testimonials...
yesterday
by j.sälli
15
https://www.redeye.se/research/1180791/optomed-strong-h2-ahead
yesterday
by Bob Fleming
14
This deal with Big Pharma / AZ is invaluable to Optomed. Thanks to it, Optomed’s BRAND VALUE globally will rise to a whole new level, and this will facilitate all other business. Waiting for the news on the deal…
10 hours ago
by j.sälli
12
Now there’s finally some commentary on what was left out of the Inderes interview. BF is ready at the starting blocks, all the documents are ready, and the business plan is being polished. This is a binary case as well. As for the China JV, trials are underway and Wiser is handling...
yesterday
by Nakki Taskupiilo
12
There are many ways to interpret that. If you look at Himberg’s body language, things are cooking in the oven and moving forward. I wouldn’t be worried at all; it will definitely come through.
9 hours ago
by Dr.Feelgood
11
I listened to the Redeye interview. A Big Pharma partnership would also require investments from Optomed, and the revenue/returns are a long-term prospect. Everything is ready, but it is being considered. It doesn’t seem like Optomed is currently able to invest in that. The cash ...
11 hours ago
by Stallion
4
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.11
2026

Interim report Q3'26

18.2
2027

Annual report '26

4.5
2027

Interim report Q1'27

Press release18.08.2026, 13.10

Redeye: Optomed (Q2 Review): Sales miss offset by strong gross margin and cost control

Optomed
Optomed Q2'26: Salget af udstyr halter, men de løbende indtægter vokser
Research17.08.2026, 07.00 by
Juha Kinnunen

Optomed Q2'26: Salget af udstyr halter, men de løbende indtægter vokser

Optomeds omsætning og resultat i 2. kvartal lå markant under vores forventninger, da salget af udstyr fortsat var trægt. Det positive i regnskabsmeddelelsen var den fortsatte vækst i Aurora AEYE-salget, reducerede omkostninger, en tydeligt forbedret pengestrøm og en rekordhøj bruttofortjeneste.

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Tauriainen

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Leppänen

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Wen

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Salonen

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Lee

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Calarco

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Badlani

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Mäkinen

Optomed
Regulatory press release14.08.2026, 08.30

Optomed Oyj: Directed share issue without payment to implement Board remuneration

Optomed
Regulatory press release14.08.2026, 08.30

Optomed Oyj: Optomed's financial reporting in 2027

Optomed
Regulatory press release14.08.2026, 08.00

Optomed Plc: Half-year report January - June 2026

Optomed
Optomed Q2'26 preview: Vi forventer tilbagevenden til vækst og overvåger pengestrømmen
Analyst Comment11.08.2026, 07.02 by
Juha Kinnunen

Optomed Q2'26 preview: Vi forventer tilbagevenden til vækst og overvåger pengestrømmen

Vi estimerer, at omsætningen er steget, efterhånden som salget af udstyr er kommet sig efter et svagt første halvår.

Optomed
Press release23.06.2026, 09.43

Redeye: Optomed: Solid device order

Optomed
Optomed modtog en udstyrsordre på 1,8 MEUR fra USA
Analyst Comment22.06.2026, 06.58 by
Atte Riikola

Optomed modtog en udstyrsordre på 1,8 MEUR fra USA

Ordren overstiger hele årets første halvårs omsætning for udstyr og styrker pengestrømmen.

Optomed
Regulatory press release18.06.2026, 16.30

Inside Information: Optomed receives a large order in the US

Optomed
Press release11.05.2026, 15.16

Redeye: Optomed (Q1 Interview): Expecting normalised sales in upcoming quarters

Optomed
Regulatory press release08.05.2026, 19.00

Optomed Oyj: Decisions of the Organization Meeting of Optomed's Board of Directors

Optomed
Regulatory press release08.05.2026, 13.30

Optomed Oyj: Decisions of the Annual General Meeting

Optomed